INFLAMISTRAT BIOCHIP

EARLY DIAGNOSIS CAN MAKE A DIFFERENCE

Randox MultiSTAT breaks new ground in critical care research, data‑driven risk stratification improves patient outcomes in acute respiratory distress syndrome (ARDS) patients by distinguishing between two consistently identified phenotypes.

APPLICATIONS

Stratifies Into:

Hyperinflammatory

or

Hypoinflammatory

SOLUTION

Patient Pathway with Evidence MultiSTAT

1

Patient presents with ARDS symptoms

2

Immediate testing with Evidence MultiSTAT

3

Aids with rapid phenotype identification in 36 minutes

4

Tailored and targeted treatment plans

RESULTS IN 36 MINUTES

marketing@randox.com

 I 

randox.com